The livestream starts on 29 October 2020 at 18:00 CETWelcome and introduction18:00 – 18:10 CETSchnell O (Munich, Germany)Cardiometabolic Center of Excellence – a model to improve guideline implementation, quality of care and outcomes in patients with Type 2 Diabetes and Cardiovascular Disease18:10 – 18:35Kosiborod M (Kansas City, USA)Obesity – Risk factor and treatment target18:35 – 19:00Blueher M (Leipzig, Germany)Discussion19:00 – 19:30See you on Friday, 30 October 2020 at 08:30 CETDiabetes mellitus in COVID 19 – Risks and therapeutic strategies08:30 – 08:55Forst T (Mannheim, Germany)CVOT results translated into Primary Care Diabetes Guidelines and Recommendations – Gaps and Opportunities08:55 – 09:20Cos Claramunt FX (Barcelona, Spain)Primary prevention of CVD in the light of current diabetes guidelines09:20 – 09:55Mathieu C (Leuven, Belgium)Living guidelines: On the dynamic updating of recommendations09:55 – 10:15Vandvik PO (Oslo, Norway)Discussion10:15 – 10:30Unmet needs in diabetic kidney disease11:00 - 11:20Fioretto P (Padova, Italy)Finerenone – Outcomes in chronic kidney disease and type 2 diabetes11:20 - 11:40Rossing P (Copenhagen, Denmark)Discussion11:40 - 12:00Dapa-CKD – From clinical evidence to clinical practice12:00 - 12:20Heerspink HL (Groningen, Netherlands)SGLT2-Is in diabetes and cardio-renal management: a class effect?12:20 - 12:40Standl E (Munich, Germany) Discussion12:40 - 13:00Diabetes, kidney disease and heart failure: Novel outcome studies and treatment options (2)13:30 - 14:30 CETChair: Giorgino F (Bari, Italy), Wanner C (Wuerzburg, Germany)SGLT2 inhibitors in the prevention and treatment of heart failure: evidence from CVOTs and implications13:30 - 13:50Sattar N (Glasgow, Scotland)Commentary: Novel outcomes on SGLT-2 Is: Practical Considerations13:50 - 14:00Rodbard H (Rockville, USA)Panel Discussion: Positioning of SGLT2 inhibitors and MRAs in the management of chronic diseases14:00 - 14:30AllImplications of the initial eGFR response to SGLT2 inhibition with empagliflozin on CV and kidney outcomes: the ‘eGFR dip’ in EMPA-REG OUTCOME14:30 - 15:00Kraus B et al. (Würzburg, Germany)Very high cardio vascular risk according to 2019 ESC EASD guidelines and coronary artery calcification scoreValensi P et al. (Paris, France)Changes of the plasma mRNA levels of some genes in patients with type 2 diabetes mellitusSaenko Y et al. (Kiev, Ukraine)Central obesity is associated with increased risk of hospitalization or mortality due to heart failure in adults with type 1 diabetesParente E et al. (Helsinki, Finland)GLP-1 RA: Update 202016:15 - 17:30 CETChair: Schnell O (Munich, Germany), Standl E (Munich, Germany)Latest evidence on GLP-1RAs mechanism of action on the cardiovascular system16:15 - 16:35Lehrke M (Aachen, Germany)Heterogeneity and similarities in GLP-1RA CVOTs: focus on specific outcomes16:35 - 16:55Giorgino F (Bari, Italy)Commentary: Novel outcomes on GLP-1-RAs: Practical Considerations16:55 - 17:10Gallwitz B (Tuebingen, Germany)Discussion17:10 - 17:30Abstract Awards and Closing17:30 - 17:45 CETSchnell O (Munich, Germany)Thank you for your attendance and your contribution to the Virtual CVOT Summit 2020. See you next year!We will be right back.End of congress
Log in with email address and password.
To log in you need to create a password:
